New London Major Early-Phase Contract Research Center Opened on Rare Disease Day

March 1, 2017 at 4:54 AM

Richmond Pharmacology, unit of the UK’s leading premature-phase contract research organisations, have today opened their unaccustomed research facility in London Bridge – at the locality formerly known as the Guy’s Drug Research Unit. The touch is a significant boost to the UK’s efforts to tarry to grow as a global hub for Life Sciences, an area of strategic significance outlined in the Government’s new industrial strategy.

6174653936_O62A2354

With Richmond having already conducted over 300 studies in London because that their establishment in 2001, the unused facility will provide a central London base as far as concerns Richmond Pharmacology’s further research utilizing their enhanced capabilities in delivering creation-leading, early-phase clinical trials. The locality is on the doorstep of different world renowned teaching hospitals which determine further enhance Richmond’s established collaboration with London’s leading university and education hospitals.

Richmond Pharmacology specialize in conducting ~us and cutting edge trials which are extremely respected by the pharmaceutical industry and regulatory persons in office responsible for licensing medicines worldwide, ~times in crucial disease areas such of the same kind with oncology and amyloidosis. Overall the copartnership conducts approximately 10% of all Phase I studies performed in the UK and 1 in every 100 studies worldwide.

Richmond’s judgment to expand their London research footstep was driven by:

A need to extend their database of more than 200,000 well and patient volunteers to promote their well-established fashion of recruitment under one roof during the term of trials that would be typically exist carried out in multiple centers.

London offers admittance to a large and diverse inhabitants to ensure effective patient recruitment in these trials

Their moil is strengthened through the invaluable fit it has to the plethora of upper end universities and clinicians based in London – helping to bring about the greatest developments and innovation in careful search in the UK

They abundantly support the Government’s ambition as antidote to London to be viewed as the global nave for Life Sciences, and are committed to continuing to drudge in the capital long-term to save make this a reality

Richmond Pharmacology’s actual trial in delivering standardized trial logistics and calm management by a dedicated study team reduces costs in the place of partners whilst ensuring they produce the highest character of data to uniform standards. As some indication of Richmond Pharmacology’s primeval standards, a 2014 poll of 217 clinical experimental knowledge volunteers showed that over 90% were successful to continue their relationship with Richmond.

6174653936_O62A2220

The first appearance of our new research facility, at that which was formerly known as the Guy’s Drug Research Unit, is an exciting addition to our research power, and will help us to bargain the best possible support for our clients in their be impelled to increase the effectiveness and cost efficiency of developing new drugs and taking them to market.

“The of the present day facility will enable Richmond to lay upon the most up to date careful search techniques for       base-breaking research projects and crucially, at escalade – something we think will subsist highly attractive to our clients in the UK and encircling the world.”

Dr Jorg Taubel, CEO of Richmond Pharmacology.

Clinical trials are every essential part of the process to accompany new healthcare products to patients. London and the UK offers every ideal location for clinical studies. London with 8.3 million NHS patients, a third of which were born overseas, provides every excellent platform for clinical research organisations like Richmond Pharmacology.”

Sarah Haywood, Chief Executive Officer of Med City UK.

Case Study: Rare Diseases Research

Related Stories

Richmond conducted a clinical inquiry trial on an investigational drug in opposition to patients with heart failure. This clinical essay was delivered in conjunction with the National Amyloidosis Centre (NAC) at London’s Royal Free Hospital – who possess more patients than they are typically dexterous to enrol in just one study.

Utilising Richmond’s clinical trials platform to cook the bulk of the associated drudge, the NAC was able to overture more patients the opportunity to have a part in in a study that they may in other respects not have had access to.

The Study:

The study tried 21 subjects across both sites, 19 of that were conducted at Richmond’s clinical research center. There were three clear benefits toward the pharmaceutical company, including:

Timelines were reduced proper to expanded capacity meaning the investigators could aim at out more patients for enrolment

Funds were utilized efficiently through standardized ordeal logistics and patient management by a dedicated study team granted by Richmond

Enhanced and else consistent data

The collaboration resulted in sharp benefits for wider parties too, including:

NAC earned memory as the largest recruiting center worldwide on account of this trial

More patients got access to a trial/treatment they in other respects would be unable to join

Richmond generated scrutiny income for London’s research community

Source:

Richmond Pharmacology

So tolerate yourself to focus on the pictures and paroxysm them to the tools you may require, instead of the other way on all sides.

Both comments and pings are currently closed.